Caris swollen IPO that planned, looking for $ 5.7BN

Caris Science, which specializes use artificial disease, target monitoring, raising its offer prices

The IMVING, Texas-Based Public announces the intention to list at the time of the time of the food analysis, RNA, and proteins.

It was a plan of $ 23.5 million in offer of $ 19 to $ 20 to $ 16, $ 18, $ 18, if IPO is completed at the end of that level.

Methods of precision drugs – mainly used as development tools, authentication, medical information, and tissue sample.

The last date of November, it refers to the FDA approval for Mi Cancan Securities, which opened the target for a solid tumor. In the first quarter, it recorded nearly $ 121 million, about 50% in the same time Kga, and Xenncor to find goals and medication.

For example, Merck is working with 1.4 billion colleagues that will use its tools for the design of antibiotics (ads) for cancer.

IPO comes only a few weeks after caris raised in $ 168 million in 2018.

DIDD Dean Halbert, Caris’ Halis’ Halis’, Carish, Carasish, CAIRMANS and Storegan Support.

He added: “We believe that this will create a chance to prevent our solution to protecting the most chronic diseases during the first phase.”

“As we specialize in symbols today, we also believe that usually, it can be used in the world, legal disorders, legal disorders, and so on.”